Erik Wang to Drug Evaluation, Preclinical
This is a "connection" page, showing publications Erik Wang has written about Drug Evaluation, Preclinical.
Connection Strength
0.504
-
Wang EY, Kuzmanov U, Smith JB, Dou W, Rafatian N, Lai BFL, Lu RXZ, Wu Q, Yazbeck J, Zhang XO, Sun Y, Gramolini A, Radisic M. An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy. J Mol Cell Cardiol. 2021 11; 160:97-110.
Score: 0.179
-
Savoji H, Mohammadi MH, Rafatian N, Toroghi MK, Wang EY, Zhao Y, Korolj A, Ahadian S, Radisic M. Cardiovascular disease models: A game changing paradigm in drug discovery and screening. Biomaterials. 2019 04; 198:3-26.
Score: 0.148
-
Conant G, Lai BFL, Lu RXZ, Korolj A, Wang EY, Radisic M. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. Stem Cell Rev Rep. 2017 Jun; 13(3):335-346.
Score: 0.135
-
Kuzmanov U, Wang EY, Vanderlaan R, Kim DH, Lee SH, Hadipour-Lakmehsari S, Guo H, Zhao Y, McFadden M, Sharma P, Billia F, Radisic M, Gramolini A, Emili A. Mapping signalling perturbations in myocardial fibrosis via the integrative phosphoproteomic profiling of tissue from diverse sources. Nat Biomed Eng. 2020 09; 4(9):889-900.
Score: 0.042